Ovid Therapeutics Inc. 8-K Filing
Ticker: OVID · Form: 8-K · Filed: Dec 11, 2025 · CIK: 1636651
| Field | Detail |
|---|---|
| Company | Ovid Therapeutics Inc. (OVID) |
| Form Type | 8-K |
| Filed Date | Dec 11, 2025 |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Ovid Therapeutics Inc. (ticker: OVID) to the SEC on Dec 11, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ich registered Common Stock, par value $0.001 per share OVID The Nasdaq Stock Market).
How long is this filing?
Ovid Therapeutics Inc.'s 8-K filing is 3 pages with approximately 778 words. Estimated reading time is 3 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 778 words · 3 min read · ~3 pages · Grade level 14.8 · Accepted 2025-12-11 13:58:35
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share OVID The Nasdaq Stock Market
Filing Documents
- ovid-20251211.htm (8-K) — 37KB
- 0001636651-25-000017.txt ( ) — 151KB
- ovid-20251211.xsd (EX-101.SCH) — 2KB
- ovid-20251211_lab.xml (EX-101.LAB) — 22KB
- ovid-20251211_pre.xml (EX-101.PRE) — 13KB
- ovid-20251211_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. Ovid Therapeutics Inc. (the " Company ") held a special meeting of stockholders (the " Special Meeting ") on December 11, 2025. As of October 31, 2025, the record date for the Special Meeting, there were 71,212,353 shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), outstanding and entitled to vote on the proposals presented at the Special Meeting, of which 38,044,680 shares, or 53.42%, were present in person or represented by proxy at the meeting, which constituted a quorum. Summarized below are descriptions of the proposals voted on at the Special Meeting and the final results for each of the proposals. The proposals set forth below are described in detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 7, 2025. Proposal 1 : Approval of the Increase in Authorized Shares of Common Stock The Company's stockholders approved an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended to date, to increase the number of authorized shares of the Company's Common Stock from 125,000,000 to 315,000,000, by the votes set forth in the table below: For Against Abstain 34,225,378 1,453,502 2,365,800 Proposal 2: Approval of the Conversion of Series B Preferred Stock and Exercise of the Series A Warrants and Series B Warrants The Company's stockholders approved, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of Common Stock upon the conversion of the Company's Series B Convertible Preferred Stock, par value $0.001 per share (the "Series B Preferred Stock"), and the exercise of Series A Warrants to purchase shares of Common Stock and/or pre-funded warrants (the "Pre-Funded Warrants") to purchase Common Stock (the "Series A Warrants") and Series B Warrants to purchase shares of Common Stock and/or Pre-Funded Warrants (the "Series B Warrants"), by the vo
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 11, 2025 OVID THERAPEUTICS INC. By: /s/ Jeffrey Rona Jeffrey Rona Chief Business and Financial Officer